Cannabinoid Hyperemesis Syndrome - A Case Report of an uncommon condition

نویسندگان

چکیده

Introduction The increasing prevalence of cannabis use in the world requires awareness cannabis-related disorders such as cannabinoid hyperemesis syndrome (CHS). CHS is characterized by cyclic episodes nausea, vomiting and abdominal pain, affecting chronic users, who usually recur to hot showers relief symptoms. pathophysiology underlying this still unclear. Despite well-established anti-emetic properties cannabis, there evidence its paradoxical effects on gastrointestinal tract central nervous system. Objectives authors pretend inform readers about rare Cannabinoid Hyperemesis Syndrome Methods describe a case 22 years old patient with use, intractable nausea vomiting, bring attention that condition exists underdiagnosed. Results should be strongly considered differential diagnosis persistent patients reports showers. In acute setting, supportive care intravenous fluids, dopamine antagonists, topical capsaicin cream, avoidance narcotic medications has shown some benefit. However, cessation appears best treatment. Conclusions will continue rise parallel worldwide potency. So, health professionals must aware syndrome, diagnosis, treatment, provide better avoid overlooking CHS. Further research required elicit exact mechanism additional therapies for condition. Disclosure Interest None Declared

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology.

Cannabis is the most widely used illicit drug in the United States, with lifetime prevalence of use estimated at 42% to 46%. The antiemetic properties of cannabis are well-known by the medical community and the general public; however, less well-recognized is the paradoxical potential for certain chronic users to develop hyperemesis. We describe in this case a patient with prior extensive work-...

متن کامل

Cannabinoid hyperemesis syndrome.

Legalization of marijuana use will increase the number of people who will become long-term users. A prior medical record review study in Australia, in 2004, identified 19 chronic marijuana users who entered the emergency department with recurrent vomiting associated with abdominal pain. Routine treatment of the nausea and vomiting, associated with the chronic marijuana abuse, with antiemetics i...

متن کامل

Cannabinoid hyperemesis syndrome.

Introduction Marijuana is used in the United States and worldwide. It sometimes is used by patients, most generally illegally, for its antiemetic properties. Paradoxically, it actually can cause nausea and vomiting with abdominal pain in some patients. In recent years, there has been recognition of a new clinical condition known as Cannabinoid Hyperemesis Syndrome (CHS). This syndrome was first...

متن کامل

Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome.

To the Editor: In their editorial on opiate overdose, Berge and Burkle list the release of new opioid drugs, the aggressive marketing to physicians, the declaration of pain as “the fifth vital sign,” and the increased willingness of physicians to treat noncancer pain with opioids as the measures that led to the explosion of sales of prescription opioid pain relievers. It is imperative that 3 ot...

متن کامل

Case Series and a Review of Cannabinoid Hyperemesis Syndrome

Cannabis is a widely used drug of abuse in the United States (US) with over 16.7 million users reported in 2009 [1]. Known for its psychedelic effects, it is mostly commonly abused by young individuals. Cannabis is also utilized by the medical field for a number of medicinal purposes, some of which have been well known for centuries. Most recently, the role of Cannabis as a medicinal agent has ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: European Psychiatry

سال: 2023

ISSN: ['0924-9338', '1778-3585']

DOI: https://doi.org/10.1192/j.eurpsy.2023.1615